NYSEAMERICAN : KAPA
Kairos Pharma, Ltd. — Key statistics
Healthcare · Biotechnology · United States
Last price 0.53 USD (Oct 30, 2026, 4:00 PM) · Market cap 1.79M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.79M |
| Enterprise Value | -831,837 |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 3.39M |
| Shares Outstanding | 3.39M |
| Shares Change (YoY) | +46.73% |
| Shares Change (QoQ) | +1.95% |
| Owned by Insiders (%) | 28.80% |
| Owned by Institutions (%) | 7.63% |
| Float | 2.25M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.39 |
| P/TBV Ratio | 0.43 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 11.98 |
| Quick Ratio | 9.91 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -113.96% |
| Return on Assets (ROA) | -66.91% |
| Return on Invested Capital (ROIC) | -73.09% |
| Return on Capital Employed (ROCE) | -142.14% |
| Weighted Average Cost of Capital (WACC) | 12.20% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.45M |
| Employee Count | 4 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.45 |
| 52-Week Price Change | -93.12% |
| 50-Day Moving Average | 1.33 |
| 200-Day Moving Average | 3.05 |
| Relative Strength Index (RSI) | 19.74 |
| Average Volume (20 Days) | 984,567 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 134,519 |
| Short Previous Month | 114,388 |
| Short % of Shares Out | 3.97% |
| Short % of Float | 5.99% |
| Short Ratio (days to cover) | 0.16 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -5.96M |
| Pretax Income | -5.81M |
| Net Income | -5.81M |
| EBITDA | -5.82M |
| EBIT | -5.96M |
| Earnings Per Share (EPS) | -$1.95 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 2.63M |
| Total Debt | n/a |
| Net Cash | 2.63M |
| Net Cash Per Share | $0.78 |
| Equity (Book Value) | 4.19M |
| Book Value Per Share | 1.37 |
| Working Capital | 2.91M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -3.97M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 142,000 |
| Net Borrowing | 3.38M |
| Free Cash Flow | -3.97M |
| FCF Per Share | -$1.17 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -46.73% |
| Shareholder Yield | -46.73% |
| Earnings Yield | -367.25% |
| FCF Yield | -221.27% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $49.00 |
| Price Target Difference | 9,145.28% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Sep 1, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:7 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |